Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RXRX Stock Chart & Stats
$3.25
-$0.34(-4.54%)
At close: 4:00 PM EST
$3.25
-$0.34(-4.54%)
Day’s Range― - ―
52-Week Range$2.98 - $7.18
Previous CloseN/A
Volume5.68M
Average Volume (3M)16.60M
Market Cap
$1.72B
Enterprise Value$788.04M
Total Cash (Recent Filing)$743.29M
Total Debt (Recent Filing)$77.97M
Price to Earnings (P/E)―
Beta3.38
Next Earnings
May 11, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding521,950,700
10 Day Avg. Volume14,278,360
30 Day Avg. Volume16,601,787
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.62
Price to Sales (P/S)24.50
P/FCF Ratio-4.84
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue10.57
Enterprise Value/Gross Profit-32.98
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$7.00Price Target Upside115.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.98
Revenue Forecast (FY)$84.12M
Bulls Say, Bears Say
Bulls Say
Cash Runway And Expense ManagementImproved cash burn discipline and lower operating expenses extend the company's financial runway, enabling continued development and partnership activities without immediate capital raises.
Clinical Data And Label ExpansionStrong and durable TUPELO trial responses for REC-4881 in FAP patients and expansion of the eligible age population broaden the drug's addressable market and support significant commercial upside.
Partnerships And Milestone FundingMilestone payments and program starts from major pharmaceutical partners supply non-dilutive funding and external validation of the AI-driven discovery platform, reducing near-term financing pressure.
Bears Say
Cash Flow And Financing RiskMissed operating cash flow guidance combined with substantial cash burn increases reliance on further expense cuts or external financing, elevating dilution and execution risk if cost control weakens.
Platform Validation RiskSustained valuation improvement depends on repeatable clinical wins that demonstrate the AI-derived discovery approach can produce differentiated medicines, so isolated successes may not trigger a durable rerating.
Regulatory And Safety UncertaintyRegulatory clarity, safety outcomes, and biomarker-driven patient selection will be decisive for securing registrational pathways and could limit market access if results are unfavorable.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $2.98 and its highest was $7.18 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Recursion Pharmaceuticals’s market cap is $1.72B.
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is May 11, 2026 which is in 49 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on Feb 25, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.301 by $0.091.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -0.25.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 521,950,700 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.301. Following the earnings report the stock price went up 6.799%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Currently, no hedge funds are holding shares in RXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recursion Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (115.38% Upside)
$7.00 (115.38% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $588.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.84%
12-Months-Change
Fundamentals
Return on Equity
-63.98%
Trailing 12-Months
Asset Growth
5.51%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Company Deck
RXRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful progress across clinical proof-of-concept (notably REC-4881 in FAP), strong platform and discovery efficiency metrics, and material partnership inflows that collectively extend runway and validate the AI-enabled strategy. Offsetting these positives are concentration of important catalysts in the near term, industry-wide high failure probabilities, outstanding clinical validation needs for tolerability claims, and reliance on future partner milestones to sustain funding beyond early 2028. On balance, the highlights (clinical proof of concept, cash runway extension, 35% cost reduction, platform scale, and repeatable partner milestones) meaningfully outweigh the program and funding risks cited, supporting an overall positive tone while acknowledging near-term binary execution risks.View all RXRX earnings summariesRXRX Stock 12 Month Forecast
Average Price Target
$7.00
▲(115.38% Upside)
Technical Analysis
Agios Pharma
―
Galapagos
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
2.99% Insiders
12.14% Mutual Funds
24.40% Other Institutional Investors
35.86% Public Companies and Individual Investors